Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company has...
-
NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that its Chief Executive...
-
NEW YORK, Oct. 06, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that its Chief Executive...
-
RAFA to Distribute Axim’s Award-Winning Cannabinoid Chewing Gum CanChew®NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), an innovative biotechnology company...
-
NEW YORK, July 11, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech), a world leader in hemp cannabinoid research and development, launched the Company’s community outreach and...
-
NEW YORK, May 17, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM) is pleased to announce to shareholders and the public that the Company is launching human dermatological clinical...
-
NEW YORK, March 31, 2016 (GLOBE NEWSWIRE) -- Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotechnologies, Inc. (OTC:AXIM) was recently appointed to the American Pain...
-
NEW YORK, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotechnologies, Inc. (OTC:AXIM) shares the hemp innovator’s vision and...
-
NEW YORK, Jan. 28, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies (OTC:AXIM) is proud to announce the following finance and community outreach-focused additions to the Company’s advisory...
-
NEW YORK, Jan. 28, 2016 (GLOBE NEWSWIRE) -- A groundbreaking story by Reuters global news agency profiled AXIM® Biotechnologies, Inc. (OTC:AXIM) and the company’s upcoming clinical trials on the...